Clinical trial

Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223

NCT02981797

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

OTHER · Unmapped registry intervention Blood Collection During Standard of Care Treatment Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Assess Gamma H2AX Positivity in Circulating Prostate Cancer Cells Before and After Radium 223

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2015-07-22

PhaseN/A

Conditions

Prostate Cancerverified · MONDO: prostate cancer

Prostate Adenocarcinomaverified · MONDO: prostate adenocarcinoma

Interventions

Blood Collection During Standard of Care TreatmentOTHER

Sponsors & collaborators

H. Lee Moffitt Cancer Center and Research Institutelead sponsor

Bayercollaborator

Mapped research locations

TampaFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02981797 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.